|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.042 SGD | +2.44% |
|
+5.00% | -6.67% |
| Mar. 12 | Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer | MT |
| Mar. 12 | IX Biopharma Introduces New Sublingual Wafer | MT |
iX Biopharma Ltd. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported sales was SGD 5.91 million compared to SGD 14.39 million a year ago. Net loss was SGD 9.62 million compared to SGD 4.6 million a year ago.
Basic loss per share from continuing operations was SGD 0.0126 compared to SGD 0.0062 a year ago. Diluted loss per share from continuing operations was SGD 0.0126 compared to SGD 0.0062 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -6.67% | 23.68M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
IX BIOPHARMA LTD. 
